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RESPONSE CURVES
By Kelly R. Moran∗, David Dunson∗ and Amy H. Herring∗
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Today there are approximately 85,000 chemicals regulated under
the Toxic Substances Control Act, with around 2,000 new chemicals
introduced each year. It is impossible to screen all of these chemicals
for potential toxic effects either via full organism in vivo studies or in
vitro high-throughput screening (HTS) programs. Toxicologists face
the challenge of choosing which chemicals to screen, and predicting
the toxicity of as-yet-unscreened chemicals. Our goal is to describe
how variation in chemical structure relates to variation in toxicolog-
ical response to enable in silico toxicity characterization designed to
meet both of these challenges. With our Bayesian partially Supervised
Sparse and Smooth Factor Analysis (BS3FA) model, we learn a dis-
tance between chemicals targeted to toxicity, rather than one based
on molecular structure alone. Our model also enables the prediction
of chemical dose-response profiles based on chemical structure (that
is, without in vivo or in vitro testing) by taking advantage of a large
database of chemicals that have already been tested for toxicity in
HTS programs. We show superior simulation performance in distance
learning and modest to large gains in predictive ability compared to
existing methods. Results from the high-throughput screening data
application elucidate the relationship between chemical structure and
a toxicity-relevant high-throughput assay. An R package for BS3FA
is available online at https://github.com/kelrenmor/bs3fa.
1. Introduction. Daily life involves being exposed to a variety of chemical substances from
diverse sources and at varying concentrations. A myriad of legislation and regulatory bodies work to
assess consumer and industrial products for toxicity and reduce exposure risk. The Toxic Substances
Control Act (TSCA), passed by Congress in 1976 and administered by the US Environmental
Protection Agency (EPA), regulates the bulk of1 new and existing chemicals in the United States
(US). When the TSCA was enacted, around 60,000 chemicals were grandfathered into the program
and effectively considered safe for use. The EPA has struggled to catch up on this backlog while
also keeping up with the rate of new introductions (roughly 2,000 chemicals per year) as they assess
chemicals for potential toxicity. High-throughput screening methods have proved vital to this effort
as they allow researchers to quickly conduct millions of tests.
The EPA’s Toxicity Forecaster (ToxCast) research program, in which thousands of chemicals are
tested in more than 700 high-throughput assay endpoints, is used to prioritize, screen and evaluate
chemicals for potential toxic effects (Dix et al., 2006; Judson et al., 2009; Kavlock et al., 2012).
However, even high-throughput toxicity screening (HTS) programs, which allow for the relatively
cheap and fast collection of dose-response information via in vitro studies rather than full organism
Keywords and phrases: Dimension reduction, Distance learning, Functional prediction, High-throughput screening,
Toxicity, ToxCast, QSAR
1Exceptions regulated under different legislation include foods and food additives, drugs, cosmetics, pesticides,
tobacco products, research substances used in small quantities, and radioactive materials and waste.
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in vivo studies, are still too slow and expensive to be able to study all chemicals. In silico studies,
i.e. those performed via computer modeling rather than in the lab, can be used to guide the
design of and supplement the results from lab-based studies. Specifically, the characterization of
an activity relevant chemical distance in silico enables more targeted design of further in vitro
studies, increasing the efficiency of resource allocation. In addition, predicting toxicity via such
studies helps bridge the gap between the number of chemicals of interest and the number with
known toxicological profiles.
The goal of this work is to make inferences about how variation in chemical structure relates to vari-
ation in toxicological response. Sparse function-on-scalars regression models (Chen, Goldsmith and
Ogden, 2016; Barber et al., 2017; Fan and Reimherr, 2017; Kowal and Bourgeois, 2018) do this in a
limited way by selecting the important chemical structure features and giving them appropriate co-
efficients or weights. Because there are many redundant and highly correlated structure features (see
Figure 1), a PCA-esque approach that introduces latent factors related to the major directions of
variation in the molecular structure is more informative than such penalized regression approaches.
However, simply performing PCA or other unsupervised dimension reduction approaches on the
chemical structure ignores the distinction between overall variation and toxicity-relevant variation
in the molecular structure. A supervised dimension reduction approach, on the other hand, pro-
vides a coherent and flexible framework within which to describe the relationship between molecular
variation and activity variation via a shared latent subspace.
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Fig 1: Pairwise correlation between each of the 777 molecular descriptors in ToxCast for the chemicals profiled.
Dose response data and molecular structure are the two sources of information in ToxCast relevant
to addressing our goal. Explicitly, chemical i in ToxCast has two relevant pieces of information: the
vector of response observations at D doses yi = [yi(d1), . . . , yi(dD)]
′, and the vector of S molecular
features xi = [xi1, . . . , xiS ]
′. Observations yi are sparse, noisy, and not on a regular grid. For an
example see Figure 2; Chlorobenzilate has 54 observations at 11 unique doses, yet 5-Methyl-1H-
benzotriazole only has 3 doses with one observation each. Not all aspects of the feature space (i.e.
not all entries in xi) are likely to be relevant to the toxicological response.
The specific high throughput assay analyzed here is the AttaGene pregnane X receptor (PXR) as-
say. This assay targets the PXR via the xenobiotic pathway and has been shown to be related to the
body’s response to toxic substances (Kliewer, Goodwin and Willson, 2002). The tool used to quan-
titatively summarize a chemical’s molecular structure is Mold2 (Hong et al., 2008), which generates
a set of 777 numeric descriptors using the simplified molecular-input line-entry system (SMILES)
specification (Weininger, 1988). See Figure 3 for select Mold2 output for an example chemical,
and (Hong et al., 2012) for a discussion of the use of Mold2 in Quantitative Structure–Activity
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Fig 2: Left: Dose response data for example chemicals from the ToxCast ATG PXR assay (i.e., yi). Right: 2D chemical
structure diagrams for example chemicals (converted from SMILES into xi using the Mold2 software).
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Relationship (QSAR) models.
In order to coherently model both structural and toxicological response variation, we propose a
Bayesian partially Supervised Sparse and Smooth Factor Analysis (BS3FA) model. The model
assumes structured variation in the molecular features xi is driven by two sets of latent factors: call
these Fx-specific and Fshared. Fx-specific is unrelated to the toxicological response and is responsible for
structured molecular variability that does not impact toxicity. Fshared is assumed to drive variation
in the toxicological response yi, and thus is responsible for structured molecular variability that
does impact toxicity. The directions spanned by these two sets of latent factors can be thought of
as the “toxicity-irrelevant” and “toxicity-relevant” spaces, respectively.
Chemical similarity can be characterized by proximity in this latent toxicity-relevant space, enabling
a measure of distance with uncertainty quantification that is adapted to the particular response
space of interest. Such a metric is powerful because (1) it is based on a subspace driving variation in
activity, whereas proximity with respect to the full set of molecular descriptors does not necessarily
mean proximity with respect to activity (Martin, Kofron and Traphagen, 2002; Nikolova and Ja-
worska, 2003), and (2) it is purely statistically derived, requiring no knowledge of the fundamental
chemical and biological processes responsible for the activity, as such information is not always
available. Such an activity-relevant distance metric could be used by toxicologists in the design of
diverse chemical libraries or to select new compounds to augment a screening collection such as
ToxCast.
As with function-on-scalars regression approaches, the BS3FA model allows for the prediction of
activity profiles for chemicals that have not yet been screened in ToxCast. It does so by embedding
the full set of molecular features for a new chemical into the latent toxicity-relevant feature space
Fshared, and then projecting this embedding out to the activity space. The predicted dose-response
profiles can be used to generate point and interval estimates for common univariate toxicological
outcomes of interest, such as 50% activity concentration (AC50), maximum activity, or the area
under curve (AUC), which can be used in place of the as of yet unobserved in vitro results for that
chemical.
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Fig 3: Numeric values for select Mold2 traits of Bisphenol A (BPA). The chemical formula for BPA is C15H16O2, and
its SMILES descriptor is CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O.
The rest of the paper is organized as follows. First, we describe existing and potential approaches to
modeling chemical structure and activity. Then, the BS3FA model is described and its performance
is compared to that of existing algorithms on simulated data sets. Next, a detailed analysis of the
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motivating application data set is considered, where the BS3FA model is run with Mold2 chemical
features and the Attagene PXR assay from the ToxCast data set as input data. Finally, the results
are discussed and future areas of research are highlighted.
2. Background. QSAR models (see Figure 4) are based on the assumption that chemicals with
similar features are likely to have similar effects. The ToxCast data poses two main challenges for
QSAR modeling. First, it is often not trivial to characterize similarity in activity-relevant chemical
feature space well (Martin, Kofron and Traphagen, 2002; Nikolova and Jaworska, 2003). Second,
the majority of QSAR models aim to relate structure to a summary of the data across times/doses
(e.g., (Liu et al., 2011; Patel et al., 2014)) rather than to the full dose response curves.
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Fig 4: Quantitative Structure-Activity Relationship (QSAR) models predict toxicity as a function of chemical struc-
ture.
We discuss these considerations in the context of existing QSAR models and other related ap-
proaches not yet applied to QSAR models. To the authors’ knowledge, no existing approaches are
able to address the challenge of learning a low-dimensional representation for multivariate feature
data xi partially supervised by sparse functional data yi.
2.1. QSAR approaches for dose response profiles. Two existing QSAR approaches have attempted
to relate molecular descriptors to full dose response curves (Low-Kam et al., 2015; Wheeler, 2019).
In (Low-Kam et al., 2015), a Bayesian regression tree is defined over functions where each leaf
represents a different dose-response surface. This method was used to learn about the relationship
between chemical properties and observed dose-response. However, the model lacks the ability to
scale to the numbers of chemicals and molecular descriptors considered here. Furthermore, predic-
tive performance was found to be lacking in leave-one-out analysis. Finally, the code was designed
under the assumption that each chemical would be tested at the same doses with the same number
of replicates at each dose.
The Bayesian Additive Adaptive Basis Tensor Product (BAABTP) model (Wheeler, 2019) is de-
signed purely for prediction. It learns basis functions via independent Gaussian process (GP) priors
over the molecular structure space and the dose space. In the model, step one is to perform PCA on
the set of Mold2 chemical descriptors. Step two is to use the principal feature space explaining 95%
of the variation in this Mold2 descriptor set as the input to the distance kernel for the molecular
structure GPs.
The BAABTP model has two major problems, both stemming from the Gaussian process prior
over chemical structure. First, the model becomes computationally intractable when the number of
chemicals increases past a few thousand– the number of chemicals tested in the ATG PXR assay
has increased from under 1,000 up to nearly 4,000 in the time since the data were analyzed in
(Wheeler, 2019), and this number will only continue to grow. Second, the GP priors over chemical
structure rely on a concept of molecular distance based on total, rather than toxicity-relevant,
variability. Mold2 descriptors are a numeric representation of the 2D structure of a chemical. Thus,
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while the leading principal components (PCs) account for the majority of structural variability
across chemicals, these leading PCs may not be those most relevant to toxicity. Figure 5 illustrates
this phenomenon, showing that chemicals may be close in PCA-based structure space but distant
in response space. In other words, similarity in directions of highest structural variability does not
necessarily correspond to similarity in directions of highest activity variability.
Fig 5: Relationship between chemical “structure distance” and chemical “activity distance” when PCA and functional
PCA (FPCA) are performed independently on the Mold2 chemical structures and the ToxCast dose response curves.
Each point on the graph shows the Euclidean distance between the (functional) principal component scores accounting
for 95% of the variability in the data for one pair of chemicals on the (y-) x-axis.
2.2. Towards the proposed approach. Supervised and sparse functional PCA (supSFPCA) (Li,
Shen and Huang, 2016) defines a hierarchical model to provide supervision for dimension reduc-
tion of functional data by another multi-output data source. A small modification to the penalty
term used in this algorithm would allow for the opposite relation (i.e., to supervise the dimension
reduction of the feature data xi by functional dose-response data yi), but the larger issue is that
the supSFPCA algorithm is designed such that the algorithm finds directions that maximize un-
explained variability in xi (that is, what isn’t accounted for by yi) rather than finding directions
that maximize variability explained by yi. As such, this algorithm is of little use for prediction or
for learning about directions of variability of most relevance for toxicity.
Our approach was inspired by the conceptual goal of separating variability shared by xi and yi into
toxicity-relevant, toxicity-irrelevant, and noise components, similar to the idea behind the Joint and
Individual Variation Explained (JIVE) method (Lock et al., 2013). Unlike JIVE, modeling takes
place within a Bayesian framework for unified parameter estimation, prediction, and uncertainty
quantification about posterior summaries of interest, and model components are identifiable. We
utilize similar tools as the function-on-scalars regression of (Kowal and Bourgeois, 2018), imple-
menting sparsity-inducing coefficient-level priors to account for the high-dimensional predictors,
learning a flexible basis for the functional response, and imposing ordered sparsity so as to reduce
the impact of the choice of latent subspace dimension.
Like many of the approaches described in the previous sections, our model is able to predict the
dose-response profiles for new chemicals. Unlike previous models, our model is able to learn a
toxicity-relevant subspace underlying variation in both the chemical structure and toxicological
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response. This subspace can be used to describe a statistically-driven activity-relevant distance
between chemicals. It can also provide insight into how toxicity-relevant variability manifests across
both molecular structure and dose-response profiles.
3. BS3FA model. Figure 6 gives a visual representation of the BS3FA model. BS3FA is able to:
(1) learn a linear low dimensional latent space underlying both molecular structure and activity,
(2) develop a distance metric for chemicals relying only on molecular structures relevant to toxicity,
(3) handle responses observed at a sparse, irregularly spaced set of doses, and (4) enable activity
predictions for chemicals having no observed dose response information.
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Fig 6: Visual representation of the BS3FA model. Entries in X are the chemical feature descriptors from Mold2, while
entries in Y are noisy realizations of an underlying smooth dose response curve. Observations fx,1, . . . , fx,S are the
true mean of the chemical features and fy,1, . . . , fy,D are the true mean of the dose response values. Latent variables
η1, . . . , ηK , the underlying toxicity-relevant factors, are shared, and ν1, . . . , νK , the underlying toxicity-irrelevant
factors, are specific to the chemical features. Arrows denote probabilistic dependency.
3.1. Model specification. The characteristics of chemical structure and toxicological re-
sponse can likely be summarized using fewer descriptors. As shown in Figure 1, many
molecular descriptors tend to exhibit high correlation. Furthermore, their realized value can often
be attributed to some underlying trait of the molecule (e.g., many descriptors are largely driven by
molecule size; the descriptors number of carbon, number of oxygen, molecular weight, and number
of atoms in the molecule all have pairwise correlation above 0.9). Similarly, dose response pro-
files exhibit a somewhat limited range of shapes, suggesting possibly a few underlying functional
“building blocks” comprising variation in activity.
Factor modeling is a means by which to model variability in high dimensional data via an underlying
lower dimensional subspace. For some set of observations {zi}Ni=1, where zi is the P−dimensional
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vector of measurements for observation i, the traditional (non-joint) factor model is:
zi = Ληi + i, ηi ∼ NK(0, I), i ∼ NP (0,Σ0),
Σ0 = diag(σ
2
1, . . . , σ
2
P )
i = 1, . . . , N.
(1)
The prior induced on the latent zi by integrating out the unknown ηi is then:
(2) zi ∼ N(0,ΛΛ′ + Σ0),
yielding a lower dimensional representation of the covariance between measurements.
Chemical features are often non-normal (e.g. count, skewed continuous, or binary).
Many chemical descriptors from Mold2 are counts of particular elements (number of carbon, number
of oxygen, etc.).
In order to allow this framework to encompass data of mixed type, define:
xis = fs(zis), i = 1, . . . , N, s = 1, . . . , S.(3)
The particular link function fs depends on the feature specification, allowing for mixed scale data
via selection of an appropriate link by scale and type. Let fs(zis) = zis or fs(zis) = log(zis)
for continuous xis, with the latter chosen for strictly positive and positively skewed cases. Let
fs(zis) = 1(zis > 0) for binary xis, where 1(·) is an indicator function taking the value of 1 when
the argument is true and 0 when the argument is false. Categorical variables may be incorporated
under this framework by transforming the C categories into C − 1 binary variables indicating
whether or not the categorical value for that individual took a given non-baseline category value;
the result is that either none or one of the C−1 variables will take on a value of 1. Finally for count
xis, which may or may not be zero-inflated, let fs(zis) be a rounding operator such that fs(zis) = 0
if zis < 0 and fs(zis) = t if t− 1 ≤ zis < t, as specified in (Canale and Dunson, 2013).
There is likely a shared low dimensional space underlying chemical features and activ-
ity. BS3FA assumes that some underlying factors explain all of the variation in the dose response
curves and, jointly, part of the variation in the associated chemical features. Recall zi and yi
denote S− and D−dimensional (latent) continuous features and observed dose response curves, re-
spectively, for observation i. Assume each is mean centered and that the indexing of yi is such that
the function is ‘in order’ (for the ToxCast data, in order means that the D unique doses are sorted
such that the doses increase with index). Also, for notational convenience assume that functional
data yi are only observed once per index (the case of notationally awkward multiply observed doses
is explicitly addressed in the Gibbs sampler described in the Appendix). BS3FA models
zi
S×1
= Θ
S×K
ηi
K×1
+ Ξ
S×J
νi
J×1
+ ei
S×1
,
yi
D×1
= Λ
D×K
ηi
K×1
+ i
D×1
,
i = 1, . . . , N.
(4)
The form of the above model is that of a set of linked factor models. Note that although there are
three non-error component pieces (namely Θηi, Ξνi, and Ληi), there are only two unique factor
vectors: ηi and νi. These factors are highly interpretable. The term ηi represents the shared latent
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space underlying structured variability in both zi and yi (note that it appears in both factor
models). In the expression for yi it is the sole factor vector and in that for zi it is one of two factor
vectors. Thus, it is responsible for all structured variation in yi but only part of the structured
variation in zi. The term νi represents structured variation in zi that is unrelated to yi.
In the above model, the mean of zi is Θηi + Ξνi, and ei is a term for unstructured noise in zi.
Similarly, the mean of yi is Ληi, and i is the unstructured noise term for yi. The priors on the
shared factors {ηi}, the X−specific factors {νi}, and error terms are set to be those typically used
in factor analysis:
ηi ∼ NK(0, I), νi ∼ NJ(0, I),
ei ∼ NS(0,ΣX), ΣX = diag(σ2X,1, . . . , σ2X,S),
i ∼ ND(0,ΣY ), ΣY = diag(σ2Y , . . . , σ2Y ),
(5)
Homoscedastic variance is assumed for dose-response curves Y. Fix σ2X,s to 1 if feature s is binary,
for reasons of identifiability.
Note that as of yet, we have not discussed the functional nature of the yi, nor the issue of many
entries in zi likely being unrelated to yi. The following sections will describe how structure can be
imposed on Λ and Θ, respectively, in light of these considerations.
The dose-response curve data are functional in nature. Figure 2 shows the noisy observa-
tions from a set of example chemicals, but the underlying signal represents a smooth curve relating
chemical dose to response.
For functional data it is preferable to have each loading vector (i.e., each column of Λ) itself be
functional. The desired smoothness of the mean curves underlying noisy observations yi can thus
be imposed via the choice of smooth priors on the loading matrix Λ. Let λk denote the kth column
of Λ, so
Λ =
 λ1 λ2 . . . λK
 .
In order to learn rather than prescribe smooth bases, columns of Λ are modeled as D−dimensional
Gaussian processes:
(6) λk ∼ GP(0, ck(·)), ck(d, d′) = α2ke−
(d−d′)2
2`2 , k = 1, . . .K.
The Gaussian process function variance α2k is comprised of two components: a global inverse variance
term φ and a column-specific inverse variance term τk. The column-specific inverse variance term
τk utilizes the multiplicative gamma process prior of (Bhattacharya and Dunson, 2011), leading to
stochastic shrinkage of columns of Λ toward 0 by index.
α2k =
(
φτk
)−1
, τk =
k∏
h=1
δh, k = 1, . . .K,
φ ∼ Ga(gφ/2, gφ/2), δ1 ∼ Ga(a1, 1), δh ∼ Ga(a2, 1), h ≥ 2.
(7)
Following the note by (Durante, 2017) on hyperparameter selection, set a1 = 2.1 and a2 = 3.1
in equation (7). The value of gφ, the hyperparameter for the global function precision of the GP,
should be chosen to reflect the scale of the data.
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This stochastic shrinkage leads to an effective truncation of the factors and an automatically learned
dimension of the latent space so long as K is chosen large enough (whether K is adequately large
can be assessed by monitoring the convergence of α2k to 0 as k approaches K). To see why, consider
the model for yi written in expanded form: yi = λ1ηi,1 +λ2ηi,2 + . . .+λKηi,K + i. Assuming K is
large enough, as k approaches K, the vector λk should be approximately the 0-vector, meaning that
many of the later terms will contribute negligibly to the mean of yi. See Figure 7 for a visualization
of Λ and column shrinkage.
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Fig 7: Visualization of the smoothness and the shrinkage of columns of an example D = 20 by K = 3 loadings matrix
Λ. The effect is an automatic truncation of the number of factors in the model and a learned latent dimension. In this
figure columns of Λ were sampled using the kernel in equation (6) with `2 = 1 and α2k being 1,
1
25
, 1
400
for k = 1, 2, 3,
and the indices d corresponding to the length-20 vector from 0 to 4, inclusive. Note that as α2k decreases, the functions
tend to flatten.
Many features are likely unimportant for certain aspects of chemical activity. That is, if
a set of chemical descriptors has not been carefully selected to be toxicity-relevant, it is unlikely that
all are related to the shape of the dose-response curves. Even if all features are toxicity-relevant, it
is plausible that features will impact different pieces of the toxicity profile (e.g., some features may
impact the steepness of the dose-response, while others may impact the height of the final plateau).
The way to encourage such a relationship is via element-wise shrinkage, i.e. zeros in entries, of the
factor loadings matrix Θ.
Shrinkage on elements θsk of Θ is desirable because it is likely that for a given factor many features
have negligible impacts on the associated component of the functional yi. Explicitly,
Θ =

θ11 θ12 θ13 . . . θ1K
θ21 θ22 θ23 . . . θ2K
...
...
...
. . .
...
θS1 θS2 θS3 . . . θSK

There is a very rich literature proposing elaborate shrinkage and sparsity priors for factor loadings
(e.g., (Yoshida and West, 2010; Meng et al., 2010; Knowles et al., 2011; Pati et al., 2014)). We opt
for a horseshoe prior (Carvalho, Polson and Scott, 2010) modified for simple sampling (Makalic
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and Schmidt, 2016) on entries θsk of Θ:
θsk ∼ N(0, β2γ2skτ−1k ),
β2|t ∼ IG(1/2, 1/t)
γ2sk|bsk ∼ IG(1/2, 1/bsk)
{bsk}, t ∼ IG(1/2, 1),
s = 1, . . . S, k = 1, . . .K.
(8)
The horseshoe component of this prior is in the hierarchical hyper-prior on global variance term
β2 and local variance term γ2sk. The column-specific variance τ
−1
k applies stochastically increasing
shrinkage as column index increases. See Figure 8 for a visualization of Θ and column shrink-
age.
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Fig 8: Visualization of elementwise sparsity and the shrinkage of columns of an example S = 15 by K = 3 loadings
matrix Θ. The effect is an automatic truncation of the number of factors in the model and a learned latent dimension.
In this figure columns of Θ had column-specific variance τ−1k being 1,
1
25
, 1
400
for k = 1, 2, 3.
The dimension of the latent space underlying the dose response curves and of that
underlying toxicity-relevant features should be the same.
The same column-specific precision τ−1k is used for both Θ and Λ, so relative column shrinkage
is applied consistently across the two matrices. The result is the same effective truncation on the
number of latent factors in the joint space. This specification, along with the common ηi, is what
allows the shared directions of variability between yi and xi to be learned. Distance can be defined
over the η-vector with elements ηk weighted by precision τ
−1
k , to give a sense of closeness in “η
space” that reflects the true amount of information contained in each latent direction.
There is additional variability in chemical structure beyond that which impacts chem-
ical activity. Unless all chemical features were carefully hand-selected to be toxicity relevant for
the specific assay considered in the model (a tall task, and unlikely to be completely true no mat-
ter how careful the selection), accounting for variability in zi shared with yi will not capture all
structured variability in chemical features.
After accounting for the variability in zi shared with yi (via latent factor ηi), zi may still have
structured variation due to individual latent factor νi. Let z
∗
i = zi−Θηi. Then z∗i = Ξνi+ei, which
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once again looks like a traditional factor model. The direct application of priors in (Bhattacharya
and Dunson, 2011) is used for elements of Ξ. Specifically elements ξs,j of Ξ are given prior
ξs,j |κsj , ωj ∼ N(0, κ−1sj ω−1j ), ωj =
j∏
h=1
ζh, s = 1, . . . S, j = 1, . . . J,
κsj ∼ Ga(gκ/2, gκ/2), ζ1 ∼ Ga(m1, 1), ζh ∼ Ga(m2, 1), h ≥ 2.
(9)
Stochastic column-specific shrinkage via the ω−1j term removes the need to select an ideal number
of factors J and allows for simply selecting J “large enough.” This formulation also allows for
efficient Gibbs sampling of the posterior. Following the note by (Durante, 2017) on hyperparameter
selection, set m1 = 2.1 and m2 = 3.1 in equation (9). The value of gκ, the hyperparameter for the
entry-level precision terms of Ξ, should be chosen to reflect the scale of the data.
If there is in fact no additional variability in zi beyond that shared with yi, the following specifica-
tion allows for all columns of Ξ to be shrunk to 0-vectors. This case reduces to a fully joint factor
model in which all variability in zi is shared with yi.
Chemical activity is not necessarily measured on a fully observed, regularly spaced
grid. There are a handful of common dose measurements at which the majority of chemicals
are measured (see Figure 11), but there are many chemicals whose observations are less regular.
Furthermore, some chemicals have multiple observed dose response curves.
The issue of irregular spacing between the unique values associated with the indices is handled
automatically via the use of GPs for modeling columns of Λ. The covariance between points is
defined by the kernel for any pair of input values (see equation (6)) and not dependent on a regular
measurement grid.
Toxicologists may wish to report different components and/or summaries of predicted
dose-response curves. For example, they may be interested in the dose value at which the re-
sponse first exceeds some threshold, the maximum response value reached, the area under the curve,
etc. Each of these summaries provides different information about the dose response relationship.
An advantage of a Bayesian formulation is that we can obtain posterior samples for any functional
of the dose response curve trivially, with these samples then used to obtain point and interval
estimates.
3.2. Posterior computation. The posterior for the BS3FA model is not available in closed form.
However, closed form full conditional distributions of the parameters associated with the model
allow the use of a straightforward Gibbs sampler for these draws. Samples obtained directly from
this Markov chain Monte Carlo (MCMC) algorithm allow for the calculation of posterior means and
credible intervals for identifiable model components, including the predicted mean, covariance, and
noise variance of X and Y . A post-processing step to resolve rotational ambiguity and account for
label/sign switching allows for identifiability of the individual model components, including the fac-
tor scores η and loadings Λ and Θ (code modified from https://github.com/poworoznek/sparse_
bayesian_infinite_factor_models). Full details on the Gibbs sampler steps and initialization
are included in the Supplemental Materials.
3.3. Code base and reproducibility. Code for simulating data and sampling from the BS3FA model,
along with a user manual, are made available at https://github.com/kelrenmor/bs3fa. A hands-
on demonstration of the package is available at https://www.youtube.com/watch?v=qLyxBQ-
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sVcY. Code specific to this paper (i.e., to reproduce the simulations, figures, and results) is provided
in the online supplementary material.
3.4. Simulation study. Simulation studies were performed in order to assess the ability of BS3FA
to learn the true toxicity-relevant distance between chemicals, its predictive performance, and the
model fit. Two broad categories of simulations were performed: first, those in which the true data
generating process aligns with model assumptions (i.e., when data are simulated from a partially
shared latent factor model) and when it does not (i.e., when data are simulated from something
other than a factor model). In the former category, we also assess how well model sub-components
can be learned.
For all simulations, 25% of simulated “chemicals” are held out. That is, rather than withholding 25%
of dose-response observations across chemicals, we withhold all dose-response data for each hold-out
chemical. For distance performance, BS3FA is compared to Euclidean distance using all features,
PCA, and Euclidean distance using the features having coefficients whose 95% credible intervals
don’t span 0 in the Bayesian function-on-scalars regression (B-FOSR) of (Kowal and Bourgeois,
2018). For predictive performance, BS3FA is compared to the BAABTP model (Wheeler, 2019),
B-FOSR, and least absolute shrinkage and selection operator (LASSO) using each covariate, dose,
and all pairwise interactions. We attempted to also compare the MSPE of a frequentist FOSR using
the refund package in R, but the fosr.vs() function returned an error saying the dimension of
yi was not high enough relative to xi (i.e., that D was too small relative to S).
For simulations in which the true data generating process aligns with model assumptions, the true
dimension of the latent toxicity-relevant space K was varied, taking values 1, 3, and 5. For each K,
the true dimension of the latent toxicity-irrelevant space J was varied from 0 to 20 in intervals of 5.
At each combination of K and J, 100 data sets were simulated with N = 300, D = 10, S = 40. For
roughly half of the chemicals in each data set, ηi was set to a zero vector for that chemical (i.e.,
for each simulated data set, there was a 50% chance that any given chemical was non-activating).
Further simulation details are provided in the Supplemental Materials. Overall, the model does
quite well at capturing the structure of the noise variance and the true components Λ and Θ.
Figure 9 shows the correlation between entries in the true pairwise distance matrix (i.e., the Eu-
clidean distance between true latent factors η) and the predicted pairwise distance matrix for
holdout chemicals. We see that even in the case of small J, performing PCA on the S−dimensional
X matrix obscures the true distance in the latent space. As J increases, the correlation between
the chemical distance in the true η and that in either PCA space or Euclidean space drops quickly.
The BS3FA has stable high correlation across all values of J and K.
Figure 10 shows the mean squared predictive error (MSPE) for the simulated hold-out chemicals’
dose-response mean functions. Although the performance of all models deteriorates as the amount
of “superfluous” information in X increases (i.e., as J increases), the BS3FA model is the most
robust, showing superior performance across all values of K and J . The BAABTP model appears
most sensitive to the value of J, with MSPE near that of BS3FA model when J is small, but among
the worst MSPE when J is high. The LASSO model is able to perform fairly well when K is small,
but as K increases it is unable to learn the more complicated relationship between xi and yi. The
B-FOSR model exhibited unstable predictions for hold-out chemicals, leading to MSPEs far above
the visual display range shown in the figure. Thus, those results are omitted.
Pointwise coverage of the BS3FA model (shown in detail in the Supplemental Materials) remains
close to nominal across all values of K and J . The coverage of the BAABTP model decreases as J
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Fig 9: Correlation between entries in the true pairwise distance matrix (i.e., the Euclidean distance between true
latent factors η) and the predicted pairwise distance matrix for holdout chemicals. Each subplot shows the result of
100 simulations per J across methods for a given true shared subspace dimension K.
increases, another reflection of its overall poor predictive performance.
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In the ToxCast analysis following this section, we discuss results from one possible method of
deeming a chemical “activity increasing,” i.e. activating. Namely, call a chemical activating if its
95% credible interval for predicted dose response profile exceeds 0 at any point. Note that for other
assays activity suppression may also be of interest, and in these cases the definition of activity
could be relaxed to require that the credible interval does not contain zero at some point. The true
positive rate (TPR), false positive rate (FPR), and false discovery rate (FDR) of this method on
the simulated data are shown in Table 1. Across all values of K and J the TPR is generally high,
and the FPR and FDR are fairly low. Note that the TPR, FPR, and FDR increase with K, while
the TPR decreases with J. That is, the model seems more likely to identify chemicals as activating
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as the dimension of the latent toxicity-relevant space increases, but loses sensitivity when there is
more toxicity-irrelevant information.
J = 0 J = 5 J = 10 J = 15 J = 20
K = 1 0.80 (0.07) 0.76 (0.07) 0.73 (0.08) 0.70 (0.04) 0.67 (0.03)
TPR K = 3 0.97 (0.00) 0.98 (0.01) 1.00 (0.00) 0.98 (0.02) 0.97 (0.03)
K = 5 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.00) 1.00 (0.01)
K = 1 0.02 (0.02) 0.02 (0.03) 0.02 (0.02) 0.03 (0.01) 0.01 (0.01)
FPR K = 3 0.05 (0.00) 0.06 (0.01) 0.05 (0.00) 0.05 (0.04) 0.02 (0.03)
K = 5 0.09 (0.05) 0.09 (0.05) 0.14 (0.01) 0.09 (0.02) 0.05 (0.04)
K = 1 0.02 (0.03) 0.03 (0.04) 0.03 (0.03) 0.03 (0.01) 0.02 (0.02)
FDR K = 3 0.05 (0.00) 0.04 (0.02) 0.05 (0.00) 0.05 (0.04) 0.02 (0.02)
K = 5 0.08 (0.05) 0.08 (0.05) 0.12 (0.01) 0.06 (0.02) 0.05 (0.03)
Table 1: True positive rate (TPR), false positive rate (FPR), and false discovery rate (FDR) for the proposed method
of assessing whether a chemical is activating. A perfect classifier has a TPR of 1 and an FPR/FDR of 0.
When there is misalignment between the structure assumed by the BS3FA model and the true
data generating process, BS3FA is still able to predict similarly to or better than the two highest
performing competitors: BAATP and LASSO. As with the well-aligned simulation, BS3FA is robust
to increasing “superfluous” information in X. A similar story can be seen in the coverage and
distance results for the misaligned simulation. Even when the assumed latent factor model is not
the model from which data are simulated, the coverage of BS3FA is close to nominal. BAABTP, on
the other hand, suffers from much lower-than nominal coverage as “superfluous” information in X
increases. BS3FA is still able to recover a distance metric that is highly correlated with the distance
in the true relevant X dimensions. Visual results are shown in the Supplemental Materials.
4. Relating chemical structure to toxicological response. Data pre-processing steps and
results of the analysis of the ToxCast ATG PXR assay are discussed in the following subsections.
The structure of BS3FA allows for learning about structured variability in both the feature and
response space, prioritizing chemicals for future evaluation, and predicting chemical activity for
as-yet-unobserved chemicals.
4.1. ToxCast setup. Observations below the cytotoxicity limit for 3540 Phase 1, Phase 2, and
e1k chemicals tested in the AttaGene PXR assay are included in our data analysis. The structure
information for each chemical is summarized by 777 Mold2 chemical features (Hong et al., 2008).
As discussed previously, BS3FA has the advantage of being able to effectively ignore toxicity-
irrelevant features via shrinkage on elements of Θ, making the careful curation of a feature set
unnecessary.
Chemicals having no provided SMILES information (n = 405) were omitted from further analysis.
The result is 3135 chemicals having Mold2 descriptions of their chemical structure. Note that some
chemicals have identical Mold2 output. These sets of chemicals are in effect considered a single
chemical (i.e., treated as multiply observed dose response curves by the model). For analysis the
number of ‘unique’ chemical sets (i.e. the number of unique SMILES represented across the 3135
chemicals) is N = 3070. The 8 most common dose concentrations are -1.05, -0.52, -0.1, 0.3, 0.85,
1.3, 1.85, 2.3 log uM (see the vertical white bands in Figure 11), but BS3FA allows both common
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Fig 11: Missingness by dose for each chemical in the analysis. Each row is corresponds to a chemical, and each column
to a dose value (sorted in ascending order). Note that very few chemicals have observations below −2 log uM.
and unique doses. As the bulk of chemicals have no information about extremely low (< −2 log
uM) dose activity (see Figure 11), the data considered are the D = 38 unique doses ≥ −2 log
uM, out of the 56 total unique doses. Approximately 4% of chemicals have multiply observed dose
response curves, e.g. Allethrin and Clorophene from Figure 2.
Mold2 is used to generate a set of 777 numeric molecular descriptors associated with each chemical.
As noted above, some chemicals exactly shared these descriptors due to Mold2’s inability to capture
certain differentiating structures (see the Supplemental Materials for an example); these “identical”
chemicals were treated as multiply observed chemicals. After removing features having no variability
(99 total, including, e.g., features equalling 0 for all chemicals such as number of 11-membered
rings and number of Argon), features with duplicated entries (16), or features having > 99%
of chemicals sharing a feature value (99, e.g. only one chemical has any aromatic group urea
derivatives), S = 563 features remain. As a further pre-processing step, the variables are scaled
to have mean 0 and variance 1. Further information on creating and using Mold2 descriptors is
included in the Supplemental Materials.
In order to mimic the scenario of using the BS3FA model to prioritize chemicals for further screening,
we hold out all of the dose-response observations for 25% of chemicals in the data set. That is, we
provide the model with these chemicals’ structure but not their dose-response curves. Of interest
will be how similar these unobserved chemicals are to known activating chemicals, and the AC50
(the dose at 50% of maximum activity) for unobserved chemicals predicted by the model to be
activating. For the purpose of this analysis, we consider a chemical activating if the lower bound of
its 95% posterior credible interval for the expected dose response curve ever exceeds 0.
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Fig 12: Average response value at each dose in the data set (solid dots) with size proportional to the number of
observations at that dose. The dashed (grey) line shows the result of connecting each of these dose-specific averages,
whereas the solid (red) line shows the average dose response curve found via LOESS (locally weighted smoothing),
with settings discussed in the Supplemental Materials. The latter is the mean curve used to center the dose response
curves in the analysis.
The low number of observations at less common doses leads to a ‘noisy’ estimate of the average dose
response curve (see the dashed grey line in Figure 12). LOESS smoothing creates a functional mean
curve that can be subtracted from each observation prior to model fitting, a data cleaning step to
reflect the assumption that the GPs on columns of Λ are centered at 0 (this correction is added
back in after model fitting prior to assessing whether the lower credible interval is positive at any
dose). Additionally, both the structure and the dose-response matrices are scaled by their Frobenius
norms so that the scaled matrices have the same Frobenius norm (a measure of total variation);
specifically set X = c X||X||F and Y = c
Y
||Y ||F , with c some constant chosen large enough to keep
the shrinkage priors on the loadings matrices meaningful. This rescaling keeps larger matrices from
dominating when learning the shared column-specific shrinkage terms {τk} or the shared score
vectors {ηi} (e.g., when S is much larger than D, as in this setting).
We ran the sampler for 40,000 iterations. After an initial burn-in of 20,000 iterations, every 10th
sample was saved. Computation time was approximately 8 hours on a 2016 MacBook pro with a
2.9 GHz Intel Core i7 processor. Trace plots of model predictions show good mixing; these, along
with those of model components and an assessment of the sufficiency of the chosen K and J values,
are available in the Supplemental Materials.
4.2. Model components. The learned matrix Λ, shown on the left side of Figure 13, provides a
snapshot of the directions of structured variation present in the dose-response data. The first column
of Λ, shown in the top middle of Figure 13, is the dominant factor loading (i.e., the factor loading
having the largest estimated norm). Unsurprisingly, this vector takes the shape of a prototypical
dose response curve. Later columns of Λ act to provide smooth deviations from this prototypical
shape. For example, the second column characterizes a close to linear increase until leveling off at
a dose value just under 2 log uM, while the fourth column shows an initial dip below zero.
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Fig 13: Left: First 6 columns of the predicted mean of Λ. Each row represents a unique dose value. Middle and right:
Mean and 95% credible intervals for the first four columns of Λ. The dose values are given on the x-axis.
The learned matrix Θ, the values of which are shown in Figure 14, provides a snapshot of the
directions of structured toxicity-relevant variation present in the feature data. The bulk of the
estimated entries are very close to 0 due to the shrinkage effect of the horseshoe prior. The BS3FA
model structure allows us to interpret the nonzero entries of a given column of Θ as being those
related to the particular structure present in the corresponding column of Λ. For example, the
significantly non-zero entries of the first column of Θ are those associated with the prototypical
activity profile seen in the top right of Figure 13. By absolute magnitude, the largest such features
include the number of group X-C on aromatic ring, molecular regresson coefficients surface LogP
index, sum eigenvalue weighted by van der Waals distance matrix, sum of topological distance
between the vertices O and Cl, and number of Chlorine.
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Fig 14: Histogram showing entries of the predicted mean of Θ. The bulk of the estimated entries are close to 0 due
to the shrinkage effect of the horseshoe prior.
The chemicals have extreme positive values of η1 will be those for which the dose-response pro-
file has a large component due to λ1 and a large chunk of toxicity-relevant molecular variability
described by the first column of Θ. In the training set, the chemicals having the largest expected
value for η1 are Mercuric chloride, Benzyltriphenylphosphonium chloride, Sodium chlorite, 1,1-
Bis(3-cyclohexyl-4-hydroxyphenyl)cyclohexane, and Basic Blue 7. All but 1,1-Bis(3-cyclohexyl-4-
hydroxyphenyl)cyclohexane, which is a known irritant, are known toxins. These chemicals all have
in common the presence of Cl, so it is unsurprising that features involving Cl appeared amongst
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the high-value loadings components for the first column of Θ.
4.3. Distance learning. Figure 15 shows the predicted pairwise distance matrix between a set of
example chemicals. chosen as clusters of chemicals in the training set closest to specific recognizable
hold-out chemicals. Included are a cluster of similar low-activity chemicals (the training chemicals
nearest to hold-out chemical Acetaminophen) in the bottom left block, and a cluster of similar
high-activity chemicals (the training chemicals nearest to hold-out chemical Bisphenol B, which
include Bisphenol A) in the central block. A handful of miscellaneous chemicals that are fairly
isolated in η space relative to the other included chemicals are shown in the top right block.
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Fig 15: Expected distance in η space for a select set of training chemicals.
When selecting future chemicals for prioritization, one can either seek to “fill in” the space around
chemicals of known toxicity relevance, or to “venture out” into spaces not near any currently tested
chemicals. While addressing this experimental design problem is outside the scope of this work, we
assume for the sake of exposition that both possible avenues are of interest. We further assume
that the set of hold-out chemicals represents the space of options for further in vitro testing.
Assuming the central cluster of chemicals in Figure 15 is of interest for more targeted exploration,
we could select the hold-out chemicals closest to that set to test further. In terms of average distance
between each cluster member, the three closest chemicals in the hold-out set are Bisphenol B (i.e.,
our ‘seed’ chemical for this training group), Phenytoin, and 2,5-Bis(2-methylbutan-2-yl)benzene-
1,4-diol. Interestingly, in spite of their apparent structural differences research has suggested simi-
larity in action between BPA and local anesthetics such as Phenytoin (O’Reilly et al., 2012), lending
credence to this distance measure’s accounting of activity-relevant similarity.
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If, on the other hand, our goal was to test new chemicals that are least similar to observed chemicals,
then we could choose the hold-out chemicals having the largest minimum distance to a training
chemical. Assuming we chose such chemicals iteratively, we would select Iodoform (an organoiodine
compound occasionally used as a disinfectant), Triethyltin bromide (an organotin compound used
for proteomics research), and Indeno(1,2,3-cd)pyrene (an aromatic hydrocarbon that is a com-
mon environmental pollutant). That these chemicals are the most distant in η space from both
the training set and each other suggests that the model considers them to have distinctive ac-
tivity relevant variability. See Figure 16 for their structure diagrams; the predicted activity for
Indeno(1,2,3-cd)pyrene is also shown in Figure 18.
      
Fig 16: From left to right: Iodoform, Triethyltin bromide, and Indeno(1,2,3-cd)pyrene.
4.4. Prediction. Overall, the MSE between the data and the predicted dose-response profiles is 0.25
for the training chemicals and 0.29 for the hold-out chemicals. The 95% pointwise credible intervals
cover 91.4% of the training data and 89.5% of the hold-out data, respectively. Unsurprisingly, hold-
out chemicals having lower coverage also tend to have higher MSE. The pointwise coverage for
specific hold-out chemicals is inversely related to the minimum distance between that chemical
and its closest neighboring training chemical, while the MSE is directly related to the minimum
distance between that chemical and its closest neighboring training chemical. That is, as a hold-
out chemical moves farther away from other training chemicals, on average its coverage and MSE
become worse.
We say a chemical is predicted to be activating, i.e. to increase activity, if the lower bound of the
95% posterior credible interval for the predicted dose response curve exceeds zero at any point.
Figures 17 and 18 show model predicted mean dose-response (MDR) curves along with samples
of the AC50 value, i.e. the dose at which the dose response curve is at half of its maximal value,
for activating hold-out chemicals. The predicted mean and 95% posterior credible intervals for the
MDR curves are smooth due to the underlying structure of Λ. The proportion of hold-out chemicals
deemed activating by our model is nearly twice as high among the population of chemicals that
are heavily tested (i.e., that have 10 or more observations). Since chemicals that are known to have
toxic effects tend to be more heavily tested, this finding is suggestive of the model’s capability to
detect activity.
Although the predictive ability of the model is imperfect (e.g., Bisphenol B in Figure 17 is under-
predicted), overall performance appears reasonable. Particularly poorly predicted chemicals, exam-
ples of which are shown in the Supplemental Materials, tend to have shapes that differ from the
common profiles and/or be farther in η space from training data than well-predicted curves. Also
note that although the observations above the reported cytotoxicity limit were removed prior to
running the model, the hormesis shape (i.e., the downturn at the end of the predicted dose response
profile) remains prominent in highly activating chemicals because it is a feature of the first column
of Λ, which has the highest column norm and drives large scale variation across profiles.
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Fig 17: Results for heavily tested hold-out chemicals predicted by the model to be activating. MSEs from left to right
are 0.14, 0.91, and 0.19. Top: Predicted average dose-response curve (dashed black line), 95% credible interval for
expected dose-response curve (darker grey ribbon), and 95% credible interval for observed data (lighter grey ribbon).
Data (held out in training) are solid blue points. Bottom: Posterior samples of the AC50 value, i.e. the dose at which
the dose response curve is at half of its maximal value.
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Fig 18: Results for hold-out chemicals predicted by the model to be activating. MSEs from left to right are 0.03,
0.15, and 0.30. Top: Predicted average dose-response curve (dashed black line), 95% credible interval for expected
dose-response curve (darker grey ribbon), and 95% credible interval for observed data (lighter grey ribbon). Data
(held out in training) are solid blue points. Bottom: Posterior samples of the AC50 value, i.e. the dose at which the
dose response curve is at half of its maximal value.
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In the context of this experiment, we say a chemical is predicted not to increase activity, i.e. to be
non-activating, if the lower bound of the 95% posterior credible interval for the predicted MDR curve
does not exceed zero at any point. Figure 19 shows model predicted non-activating dose-response
curves for hold-out chemicals. As before, the predictions are smooth and appear reasonable relative
to the true data. On average, hold-out chemicals deemed non-activating under the criteria outlined
above have a lower maximum observed response than those deemed activating.
l
ll
l
l
l
ll
−1.0
−0.5
0.0
0.5
1.0
−2 −1 0 1 2
R
es
po
ns
e
4−Aminobenzoic acid
l
l
l
l
l
l
−1.0
−0.5
0.0
0.5
1.0
−2 −1 0 1 2
R
es
po
ns
e
6−Methyl−3−hydroxypyridine
l
l
l
l
l
l
l
l
−1.0
−0.5
0.0
0.5
1.0
−2 −1 0 1 2
R
es
po
ns
e
Hexadecanoic acid
l
l
l
l
l
l
l
l
−1.0
−0.5
0.0
0.5
1.0
−2 −1 0 1 2
R
es
po
ns
e
Dehydroacetic acid
l
l
l
l
l
l
l
l
−1.0
−0.5
0.0
0.5
1.0
−2 −1 0 1 2
R
es
po
ns
e
Acetaminophen
l
l
l
l
l
l
−1.0
−0.5
0.0
0.5
1.0
−2 −1 0 1 2
R
es
po
ns
e
Imidodicarbonic diamide
Fig 19: Results for select hold-out chemicals predicted by the model to be non-activating. MSEs from left to right, top
to bottom, are 0.27, 0.24, 0.19, 0.16, 0.27, 0.06, and 0.03. Shown are predicted average dose-response curve (dashed
black line), 95% credible interval for expected dose-response curve (darker grey ribbon), and 95% credible interval
for observed data (lighter grey ribbon). Data (held out in training) are solid blue points.
The choice of how to prioritize chemicals for future evaluation is flexible. Assuming there are in
fact no dose-response data for the hold-out chemicals, a simple scheme by which chemicals could
be selected for in vitro study based on their BS3FA predictions would be to screen all chemicals
for which the lower limit of the 1− α posterior credible interval for the MDR curve exceeds some
threshold (e.g., 0). The value of α could be selected with attention to the resources available–
a larger α would lead to more chemicals being screened, whereas a smaller α would mean only
those chemicals the model is most confident about would be screened. Once the set of chemicals
are selected for further testing, the order of screening could be determined by chemicals’ expected
AC50 value, by the maximum value of their predicted MDR curves, by the highest value taken by
the lower α/2 credible interval for expected response, by their proximity in latent space to known
toxic chemicals, or by another metric of interest.
For example, if one chooses α = 0.05, then 77% of hold-out chemicals have predicted dose response
curve lower bound that at some point exceeds 0. The 5 highest priority chemicals using the max
lower bound method would be Clomiphene citrate (1:1), Chlorethoxyfos, Surinabant, SSR 241586
HCl, and MK-578. Clomiphene citrate (1:1) (activity shown in Figure 17), the most well studied
chemical on this priority list, is a selective estrogen receptor modulator used to treat ovulatory
dysfunction in women trying to become pregnant. The closest neighbors to Clomiphene citrate
(1:1) in the training set are Toremifene citrate (also used clinically), Fenvalerate (an insecticide),
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Butachlor (an herbicide), and Chlorotrianisene (formerly used clinically). These chemicals all have
known estrogenic effects (Chlorotrianisene is actually a synthetic estrogen itself) (Nulsen, Carmon
and Hendrick, 1953; Go et al., 1999; louffe, 2000; Chang et al., 2012).
5. Conclusion. We have focused on the utility of distance learning for designing future chemical
test sets, but these pairwise distance matrices could be used in place of Euclidean distance in
any distance-based statistical analysis. This would include distance-based clustering of chemicals,
as well as kernel and Gaussian process-based models. As a specific example, the authors believe
these activity-relevant distances have the potential to improve main effects estimates in mixture
models for human health outcomes. It is likely that incorporating knowledge about similarity in
activity-relevant space (e.g., by using the toxicity-relevant pairwise distance matrix to inform a
group penalized regression model) would provide stabilization for main effects, and in turn allow
for better estimation of the interaction effects.
The designation of activating vs. not-activating in the BS3FA model is based on a posterior sum-
mary of the predicted dose-response profiles; there is no direct incorporation of the concept of a
chemical being inactive in the model itself. It may be desirable, particularly when considering as-
says having very few chemicals presenting with any activity, to probabilistically model inactivity.
For example, the dose response profile could be modeled as a mixture between the zero-vector and
the BS3FA factor model, with a learned weight on the zero vector corresponding to the probability
of inactivity.
The BS3FA model deals with the structured decomposition of a single assay and a single feature
data set. In reality, any sort of model hoping to extend to human health outcomes will need to uti-
lize information from multiple sources. In the ToxCast data set, there is not just one dose-response
curve per chemical. There are many assay endpoints of potential relevance to human toxicity.
Furthermore, there are potentially many useful chemical feature descriptors (we used Mold2, but
others include MACCS keys, Daylight Fingerprints, or Morgan Fingerprints, to name a few). Fu-
ture work will link the ideas in BS3FA to those in (Wilson, Reif and Reich, 2014) to allow for a
more direct activating/non-activating assignation and to hierarchically describe variability across
multiple assays. Extending even further, the holy grail of toxicity modeling would be an explicit
linking of multiple assay endpoints to human health data, such that human health outcomes could
be predicted from chemical structure alone.
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